Emerging data show that neoadjuvant chemotherapy combined with HER2-targeted therapy yields a higher pathologic complete response (pCR) rate and favorable disease-free and overall survival when compared with neoadjuvant chemotherapy alone in women with HER2-positive breast cancers [3–8]. This evidence concerns the gene ERBB2 and breast cancer.